ATP13A2 and Parkinson disease: Mutations in astrocytic LRRK2 (PARK8), GBA1 and ATP13A2 (PARK9) can reduce the astrocytic degradation capability to various extents and aggravate α-syn accumulation, which may promote PD development and progression.